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BACKGROUND
Obstructive sleep apnea syndrome (OSA) is a chronic sleep
disorder characterized by repeated episodes of upper airway
collapse during sleep. This leads to arterial hypoxemia and sleep
disruption and causes daytime sleepiness and several associated
dysfunctions, including cardiovascular, respiratory, metabolic,
inﬂammatory, cognitive, and behavioral disorders.1 OSA is a
relevant public health issue, with epidemiological studies showing
a prevalence of 10% in middle-aged men and 3% in middle-aged
women.2 Moreover, OSA has been associated with the develop-
ment of cardiovascular events3, 4 and resistant hypertension,5 has
a negative impact on quality of life,6 and has even been shown to
have a causative role in trafﬁc accidents.7 The application of
continuous positive airway pressure (CPAP) is a highly effective
treatment for OSA that can improve symptoms and quality of life,
decrease trafﬁc accidents and potentially lessen cardiovascular
morbidity.8, 9 Furthermore, CPAP is cost-effective.10 However, only
approximately 10% of individuals with OSA are diagnosed and
treated. This scarcity in diagnosis has direct public health
consequences due to the above-mentioned health implications
and the high economic costs associated with untreated OSA.
Currently, the diagnosis and management of OSA are
performed in highly specialized hospital-based sleep units (SUs),
where full sleep studies (polysomnography (PSG)) or respiratory
poligraphy (RP) can be conducted. However, this management
approach has proven to be insufﬁcient in identifying most OSA
cases in the population, in addition to being cost-ineffective and
generating long waiting lists.11 Given that OSA is a common
chronic disorder, we believe that all levels of a healthcare system,
especially primary care (PC), should be included in its manage-
ment.12–14 The ﬁrst trials assessing the management of OSA at the
PC level reported satisfactory results.15–19 Moreover, our group
showed that CPAP compliance did not differ between the PC and
SU setting and was more cost-effective in the PC setting.19
However, in the above studies, although OSA management
occurred at the PC level, diagnosis had always occurred in a SU.
Therefore, in the current study, we aimed to determine the
efﬁcacy and cost-effectiveness of implementing a program for the
diagnosis and management of OSA that can be conducted by PC
personnel, and we compared these outcomes to those generated
using the standard diagnosis and management protocols that are
practiced in SUs.
AIMS
The main objectives of the GESAP study are to assess the efﬁcacies
of PC and SU programs for OSA management. These assessments
will be made using the Epworth sleepiness scale (ESS) before
and for 6 months after initiating the program to assess its cost-
effectiveness based on both ESS and quality of life (EuroQol-5D).
Secondary objectives include assessments of patient satisfaction,
treatment compliance, and the number, severity, and evolution of
the treatment’s side effects.
METHODS
Design
This is an open-label, parallel, prospective, randomized controlled
trial. Figure 1 shows the study ﬂow diagram. Patients will be
consecutively included while attending visits with PC physicians
due to suspected OSA or resistant hypertension. The included
patients will be randomized by PC personnel to either PC or SU
management in a 1:1 ratio. The patients randomized to SU
management will be forwarded to the SU. Finally, after achieving
an appropriate diagnosis and completing a 6-month course of
follow-up, outcome evaluation and cost-effectiveness analysis will
be performed. This research was approved by the Ethical
Committee for Clinical Research of the Hospital Arnau de
Vilanova—Santa Maria (Lleida, Spain), and the trial has been
registered at ClinicalTrials.gov Id: NCT02234765.
Subjects
The following inclusion criteria will be applied (Table 1): patients
over 18 years of age visiting a PC unit in the region of Lleida,
Spain, because of suspected OSA, based on the presence of
chronic snoring, partner-objectiﬁed apnea and/or excessive day-
time sleepiness or because of resistant hypertension (Alcarràs,
Bordeta-Magraners, Borges Blanques, Cappont, Ciutat Jardí, Primer
Received: 8 July 2016 Accepted: 24 November 2016
1Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Rovira Roure, 80, Lleida, Spain; 2Primary Care Unit of
Tàrrega, Catalonia, Spain; 3Direcció Atenció primària Àmbit Lleida, Catalonia, Spain and 4Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES),
Madrid, Spain
Correspondence: Manuel Sánchez-de-la-Torre (sanchezdelatorre@gmail.com)
Núria Tarraubella and Jordi de Batlle contributed equally to this work.
www.nature.com/npjpcrm
Published in partnership with Primary Care Respiratory Society UK
de Maig, El Pla d’Urgell, Ponts, Tàrrega, Rambla Ferran and, Balàﬁa-
Pardinyes-Secà). All patients will be required to provide written
informed consent.
Randomization and intervention
Randomization will be performed using an automated password-
protected system, stratiﬁed by center. Each enrolled patient will
be allocated in a 1:1 ratio to either the SU or PC arm. A total of 280
patients will be randomized (140:140). The patients randomized to
the SU arm will be forwarded to the SU of Hospital Arnau de
Vilanova—Santa Maria. In the SU, the patients will be diagnosed
using PSG or RP as per usual clinical practice. Excessive daytime
sleepiness will be measured using the validated Spanish version of
the ESS.20 Patient follow-up and monitoring will be performed by
SU personnel. In the PC arm, PC physicians will administer the ESS
and request sleep testing from an external enterprise that supplies
home respiratory therapies in the study area (the personnel of this
enterprise have adequate training and expertise). Sleep tests will
be performed using RP devices that meet the requirements for
producing level III evidence proposed by the American Sleep
Disorders Association. A full report will then be forwarded to the
PC physician, who will choose an appropriate therapeutic option
and perform monitoring and follow-up. The PC physicians will
receive training from SU personnel before the study starts.
CPAP treatment
CPAP treatment will be prescribed according to the following
guidelines of the Spanish Society of Pneumology (SEPAR):1 an
apnea-hypo apnea index (AHI) ≥30 h−1 regardless of the presence
of cardiovascular comorbidity or hypersomnia or an AHI≥ 5 h−1
accompanied by excessive daytime sleepiness (ESS≥ 12) or
cardiovascular comorbidity. CPAP titration will be performed
using an automatic CPAP device (Autoset-T, Resmed, Sidney,
Australia) according to previously described methodology.21
Follow-up
All enrolled patients will undergo the same 6-month course of
follow-up regardless of study arm. Patients undergoing CPAP
treatment will be visited after 15 days, 1, 3, and 6months to assess
adherence to treatment (hours/day and pressure as provided by
the CPAP device), solve potential issues related to CPAP utilization,
and measure daytime sleepiness (ESS). CPAP pressure might be
modiﬁed, when necessary, to better suit a patient’s requirements.
Possible side effects of treatment as well as variables related to the
care and maintenance of the CPAP equipment will be collected.
Patients diagnosed with OSA who do not require CPAP treatment
will be evaluated at 3 and 6months. Finally, non-OSA patients will
be visited only at 6 months. All follow-up visits will be held at the
PC unit or SU according to the patient’s study arm.
Study variables and data collection
The following variables will be collected at recruitment and at the
6-month follow-up: (i) clinical variables, including age, sex,
daytime sleepiness (ESS), blood pressure, and drug use habits;
(ii) anthropometric variables, including weight, height, BMI, and
neck, waist and hip circumferences; (iii) comorbidities, including
depression, anxiety, hypertension, heart, neurological, or respira-
tory diseases, non-active neoplasm, diabetes, and dyslipidemia;
(iv) PSG or RP variables, including recording time, AHI, saturation
<90% (CT90); and (v) quality of life (EuroQol-5D) and work or trafﬁc
accidents. Additionally, the compliance of patients undergoing
CPAP treatment will be determined by dividing the number of
hours of use (obtained from the internal clock of the CPAP device)
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Fig. 1 Study ﬂow diagram
Table 1. Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Men and women
age >18 years
Pulmonary illness
Patient suspected to have OSA
or resistant hypertension
Advanced heart failure
(NYHA III or IV)
Associated advanced pathology
(including any active neoplasm or
tumor)
Psychiatric disorder
Restless legs syndrome
Pregnancy
Another dyssomnia or parasomnia
Previous treatment with CPAP
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by the number of days of treatment; adequate compliance will be
deﬁned as CPAP use ≥4 h/day. The ﬁnal follow-up visit will also
include an visual analog questionnaire on satisfaction about the
received care in addition to an estimation of the overall direct
costs of the treatment based on (i) sleep test costs (RP, PSG, and
titration by automatic CPAP); (ii) CPAP treatment costs;
(iii) patients’ travel costs; and (iv) healthcare costs 6 months
before and after randomization, including number of PC and SU
consultations and number and duration of emergency or day
hospital admissions. Hospital and PC costs will be assessed using
prices provided by the Catalan Institute of Health.22
Sample size calculation
According to the literature, a calculation will be performed to
support a non-inferiority analysis with ESS as the main study
variable. A loss of 30% will be assumed,23 as well as an alpha error
= 0.05, a beta error = 0.2, a non-inferiority limit of −2, and a
common standard deviation for the two groups of ±5.9 for the
principal variable.24
Statistical analysis
Efﬁcacy assessment will include per protocol analysis, excluding
subjects who do not complete the follow-up. Adjusted analysis of
covariance will be used to compare changes in ESS before and
after the intervention in each study arm (non-inferiority margin =
−2 points). χ2 tests and t-tests (or non-parametric equivalents) will
be used to compare quality of life (EuroQol-5D) and adherence to
treatment in the 2 study arms as appropriate. Stratiﬁed analyses
by CPAP treatment will be performed.
Cost-effectiveness assessment will include an intention-to-treat
analysis to assess the total costs for each arm based on treatment
effectiveness (ESS and EuroQol-5D). This will be performed using
Bayesian cost-effectiveness techniques. The cost-effectiveness
ratio of each treatment, the incremental cost-effectiveness ratio,
the cost-effectiveness plane, the net beneﬁt (NB) of each
treatment, the incremental NB, and the cost-effectiveness accept-
ability curve will be considered.
DISCUSSION
We believe that satisfactory management of the diagnosis and
treatment of patients with suspected OSA can be obtained in the
PC setting by performing actions at various levels, including the
interactive training of PC teams, the sharing of electronic medical
records between PC units and SUs, and the use of current
technology. We expect that the included patients will achieve a
comparable level of clinical response, satisfaction, treatment
compliance, and complication avoidance in both the PC and
SU settings. In addition, we expect that PC management will be
more cost-effective than the standard SU management. Overall,
we believe that this project could establish a new paradigm for
the management of a common condition that involves different
levels of care as well as new technologies, and could demonstrate
the ability to cost-effectively manage this chronic disease in the
PC setting.
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